Literature DB >> 19756443

[Reduced bone density and bone pain :osteomalacia with hypophospatemia and hypophosphaturia].

H M Findeisen1, C J Auernhammer, K G Parhofer, K A Herrmann, C la Fougere, C Weiler, R Bartl, E Koch.   

Abstract

Two patients aged 24 and 64 years presented at our hospital with similar symptoms including bone pain and muscle weakness. Basic laboratory tests and urinary diagnostics, bone densitometry and bone histology revealed severe osteomalacia with renal phosphate wasting. After the exclusion of other causes an extensive tumor search was performed due to suspected tumor-induced osteomalacia. In one patient a mesenchymal tumor was found in the thigh and completely resected. After surgery the patient showed a rapid recovery from osteomalacia. Because the search was unsuccessful in the other patient phosphorus supplementation in combination with calcitriol was started. Despite continuing renal phosphate wasting a significant increase in bone mineral density was observed.

Entities:  

Mesh:

Year:  2009        PMID: 19756443     DOI: 10.1007/s00108-009-2376-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

3.  Localisation of mesenchymal tumours by somatostatin receptor imaging.

Authors:  Suzanne M Jan de Beur; Elizabeth A Streeten; A Cahid Civelek; Edward F McCarthy; Liliana Uribe; Stephen J Marx; Olufunmilayo Onobrakpeya; Lawrence G Raisz; Nelson B Watts; Michael Sharon; Michael A Levine
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

4.  Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case.

Authors:  J L Dupond; H Mahammedi; D Prié; F Collin; H Gil; O Blagosklonov; B Ricbourg; N Meaux-Ruault; B Kantelip
Journal:  Bone       Date:  2005-03       Impact factor: 4.398

5.  Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.

Authors:  Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

Review 6.  Disorders of phosphate metabolism--pathomechanisms and management of hypophosphataemic disorders.

Authors:  Eberhard Ritz; Volker Haxsen; Martin Zeier
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2003-12       Impact factor: 4.690

7.  Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling.

Authors:  Gerben van Boekel; Janneke Ruinemans-Koerts; Frank Joosten; Paul Dijkhuizen; Adriaan van Sorge; Hans de Boer
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

8.  [Metabolic bone diseases].

Authors:  F Jakob
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

9.  Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.

Authors:  Andrew L Folpe; Julie C Fanburg-Smith; Steven D Billings; Michele Bisceglia; Franco Bertoni; Justin Y Cho; Michael J Econs; Carrie Y Inwards; Suzanne M Jan de Beur; Thomas Mentzel; Elizabeth Montgomery; Michal Michal; Markku Miettinen; Stacey E Mills; John D Reith; John X O'Connell; Andrew E Rosenberg; Brian P Rubin; Donald E Sweet; Tuyethoa N Vinh; Lester E Wold; Brett M Wehrli; Kenneth E White; Richard J Zaino; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394

10.  Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.

Authors:  Erik A Imel; Munro Peacock; Pisit Pitukcheewanont; Howard J Heller; Leanne M Ward; Dorothy Shulman; Moustapha Kassem; Paula Rackoff; Mark Zimering; Alan Dalkin; Elaine Drobny; Giacomo Colussi; Joseph L Shaker; Elizabeth H Hoogendoorn; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.